Literature DB >> 16838413

Neisseria meningitidis group B correlates of protection and assay standardization--international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005.

R Borrow1, G M Carlone, N Rosenstein, M Blake, I Feavers, D Martin, W Zollinger, J Robbins, I Aaberge, D M Granoff, E Miller, B Plikaytis, L van Alphen, J Poolman, R Rappuoli, L Danzig, J Hackell, B Danve, M Caulfield, S Lambert, D Stephens.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16838413     DOI： 10.1016/j.vaccine.2006.03.091

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


× No keyword cloud information.
  60 in total

1.  Inhibition of the alternative pathway of nonhuman infant complement by porin B2 contributes to virulence of Neisseria meningitidis in the infant rat model.

Authors:  Lisa A Lewis; David M Vu; Dan M Granoff; Sanjay Ram
Journal:  Infect Immun       Date:  2014-03-31       Impact factor: 3.441

2.  Investigation on the effect of immune selection on resistance to bactericidal antibodies to group B meningococci in vitro.

Authors:  George F Santos; Marzia Giuliani; Laura Santini; Jeanette Adu-Bobie; Mariagrazia Pizza; Rino Rappuoli; William Wacknov; John Donnelly
Journal:  Clin Vaccine Immunol       Date:  2009-08-26

3.  Selection of diverse strains to assess broad coverage of the bivalent FHbp meningococcal B vaccine.

Authors:  Shannon L Harris; Cuiwen Tan; John Perez; David Radley; Kathrin U Jansen; Annaliesa S Anderson; Thomas R Jones
Journal:  NPJ Vaccines       Date:  2020-01-29       Impact factor: 7.344

4.  Serum Bactericidal Antibody Responses of Students Immunized With a Meningococcal Serogroup B Vaccine in Response to an Outbreak on a University Campus.

Authors:  Eduardo Lujan; Kathleen Winter; Jillandra Rovaris; Qin Liu; Dan M Granoff
Journal:  Clin Infect Dis       Date:  2017-10-01       Impact factor: 9.079

5.  Serum Bactericidal Antibody Responses of Adults Immunized with the MenB-4C Vaccine against Genetically Diverse Serogroup B Meningococci.

Authors:  Serena Giuntini; Eduardo Lujan; Malick M Gibani; Christina Dold; Christine S Rollier; Andrew J Pollard; Dan M Granoff
Journal:  Clin Vaccine Immunol       Date:  2017-01-05

6.  Differential effects of therapeutic complement inhibitors on serum bactericidal activity against non-groupable meningococcal isolates recovered from patients treated with eculizumab.

Authors:  Dan M Granoff; Howard Kim; Nadav Topaz; Jessica MacNeil; Xin Wang; Lucy A McNamara
Journal:  Haematologica       Date:  2019-01-31       Impact factor: 9.941

7.  Vaccines, reverse vaccinology, and bacterial pathogenesis.

Authors:  Isabel Delany; Rino Rappuoli; Kate L Seib
Journal:  Cold Spring Harb Perspect Med       Date:  2013-05-01       Impact factor: 6.915

8.  Breadth and Duration of Meningococcal Serum Bactericidal Activity in Health Care Workers and Microbiologists Immunized with the MenB-FHbp Vaccine.

Authors:  Eduardo Lujan; Elizabeth Partridge; Serena Giuntini; Sanjay Ram; Dan M Granoff
Journal:  Clin Vaccine Immunol       Date:  2017-08-04

9.  Vaccine-induced opsonophagocytic immunity to Neisseria meningitidis group B.

Authors:  J S Plested; D M Granoff
Journal:  Clin Vaccine Immunol       Date:  2008-03-19

10.  Seroprevalence of bactericidal and anti-outer membrane vesicle antibodies to Neisseria meningitidis group B in England.

Authors:  Caroline Trotter; Jamie Findlow; Paul Balmer; Ann Holland; Rita Barchha; Nick Hamer; Nick Andrews; Elizabeth Miller; Ray Borrow
Journal:  Clin Vaccine Immunol       Date:  2007-05-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.